Dr. Emad Elquza, MD
Claim this profileUniversity of Arizona Cancer Center
Studies Colorectal Cancer
1 reported clinical trial
2 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
KRAS negative
NRAS negative
Affiliated Hospitals
More about Emad Elquza, MD
Clinical Trial Related4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Emad Elquza, MD has experience with
- Oxaliplatin
- Panitumumab
Breakdown of trials Emad Elquza, MD has run
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Emad Elquza, MD specialize in?
Emad Elquza, MD focuses on Colorectal Cancer and other conditions. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are KRAS negative.
Is Emad Elquza, MD currently recruiting for clinical trials?
No, Emad Elquza, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Emad Elquza, MD has studied deeply?
Yes, Emad Elquza, MD has studied treatments such as Oxaliplatin, Panitumumab.
What is the best way to schedule an appointment with Emad Elquza, MD?
Apply for one of the trials that Emad Elquza, MD is conducting.
What is the office address of Emad Elquza, MD?
The office of Emad Elquza, MD is located at: University of Arizona Cancer Center, Tucson, Arizona 85724 United States. This is the address for their practice at the University of Arizona Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.